Siglecf-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Siglecf-KO 基因敲除小鼠

产品编号

S-KO-06613

品系全称

C57BL/6JCya-Siglecfem1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-233186-Siglecf-B6J-VA

品系状态

使用本品系发表的文献需注明: Siglecf-KO 基因敲除小鼠 mice (Strain S-KO-06613) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
sialic acid binding Ig-like lectin F
基因别称
Siglec5,mSiglec-F
染色体号
Chr 7 (Mouse)
转录本 ID
NCBI: NM_145581 | Ensembl: ENSMUST00000012798
修饰方式
全身性基因敲除
靶向范围
Exon 1~10
敲除长度
~7.7 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:2681107Mice homozygous for a knock-out allele exhibit increased lung inflammation in response to ovalbumin challenge with increased eosinophils, delayed eosinophil resolution and impaired eosinophil apoptosis.
SiglecF,也称为Siglec-8,是一种免疫球蛋白样凝集素,属于免疫球蛋白超家族成员,主要表达于某些类型的白细胞,包括嗜酸性粒细胞、嗜碱性粒细胞和肥大细胞。SiglecF在免疫系统中具有多种功能,包括细胞粘附、信号转导和调节免疫反应。SiglecF与多种疾病的发生和发展密切相关,例如过敏性疾病、炎症性疾病和癌症等。

SiglecF在多种疾病中发挥重要作用。例如,在肺纤维化中,SiglecF+巨噬细胞被发现在纤维化微环境中富集,并具有促纤维化的作用[1]。在心肌梗死中,SiglecFhi中性粒细胞在梗死心脏中逐渐积累,并表现出独特的基因表达特征[2]。此外,SiglecFhi中性粒细胞在肿瘤免疫治疗中也发挥着重要作用,与肿瘤控制相关[3]。在肺转移瘤中,SiglecF+巨噬细胞表现出与脂质代谢相关的基因表达特征[4]。在心肌梗死中,SiglecFhi中性粒细胞在梗死心脏中逐渐积累,并表现出独特的基因表达特征[5]。在肿瘤微环境中,SiglecFhi中性粒细胞被发现在LKB1突变的肿瘤中富集,并促进肿瘤生长[6]。此外,中性粒细胞还可以转化为SiglecF+细胞,具有神经支持潜力[7]。

综上所述,SiglecF在多种疾病中发挥重要作用,参与调节免疫反应和疾病发生。SiglecF的研究有助于深入理解免疫系统的功能和疾病发生机制,为疾病的治疗和预防提供新的思路和策略。

参考文献:
1. Aran, Dvir, Looney, Agnieszka P, Liu, Leqian, Butte, Atul J, Bhattacharya, Mallar. 2019. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. In Nature immunology, 20, 163-172. doi:10.1038/s41590-018-0276-y. https://pubmed.ncbi.nlm.nih.gov/30643263/
2. Vafadarnejad, Ehsan, Rizzo, Giuseppe, Krampert, Laura, Saliba, Antoine-Emmanuel, Cochain, Clément. 2020. Dynamics of Cardiac Neutrophil Diversity in Murine Myocardial Infarction. In Circulation research, 127, e232-e249. doi:10.1161/CIRCRESAHA.120.317200. https://pubmed.ncbi.nlm.nih.gov/32811295/
3. Gungabeesoon, Jeremy, Gort-Freitas, Nicolas A, Kiss, Máté, Klein, Allon M, Pittet, Mikael J. . A neutrophil response linked to tumor control in immunotherapy. In Cell, 186, 1448-1464.e20. doi:10.1016/j.cell.2023.02.032. https://pubmed.ncbi.nlm.nih.gov/37001504/
4. Huggins, Danielle N, LaRue, Rebecca S, Wang, Ying, Williams, Jesse W, Schwertfeger, Kathryn L. 2021. Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset. In Cancer research, 81, 5284-5295. doi:10.1158/0008-5472.CAN-21-0101. https://pubmed.ncbi.nlm.nih.gov/34389631/
5. Calcagno, David M, Zhang, Claire, Toomu, Avinash, Heller Brown, Joan, King, Kevin R. 2021. SiglecF(HI) Marks Late-Stage Neutrophils of the Infarcted Heart: A Single-Cell Transcriptomic Analysis of Neutrophil Diversification. In Journal of the American Heart Association, 10, e019019. doi:10.1161/JAHA.120.019019. https://pubmed.ncbi.nlm.nih.gov/33525909/
6. Rashidfarrokhi, Ali, Pillai, Ray, Hao, Yuan, Koralov, Sergei B, Papagiannakopoulos, Thales. 2023. Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growth. In bioRxiv : the preprint server for biology, , . doi:10.1101/2023.07.15.549147. https://pubmed.ncbi.nlm.nih.gov/37502974/
7. Ogawa, Kei, Asano, Kenichi, Yotsumoto, Satoshi, Yamasoba, Tatsuya, Tanaka, Masato. 2020. Frontline Science: Conversion of neutrophils into atypical Ly6G+ SiglecF+ immune cells with neurosupportive potential in olfactory neuroepithelium. In Journal of leukocyte biology, 109, 481-496. doi:10.1002/JLB.1HI0620-190RR. https://pubmed.ncbi.nlm.nih.gov/32725843/